Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;2(4):260-4.
doi: 10.4103/2278-330X.119891.

Chronic myeloid leukemia in children and adolescents: A single center experience from Eastern India

Lalit Raut  1 , Vinay V Bohara  1 , Siddhartha S Ray  1 , Prantar Chakrabarti  1 , Utpal Chaudhuri  1
Affiliations

Chronic myeloid leukemia in children and adolescents: A single center experience from Eastern India

Lalit Raut et al. South Asian J Cancer. 2013 Oct.

Abstract

Context: Chronic Myeloid Leukemia (CML) constitutes around 3% of leukemia in the children and adolescent age group.

Aims: The aim of the study was to evaluate the characteristics at presentation and the treatment outcome of CML in the children and adolescent age group.

Settings and design: Retrospective analysis was carried out at a single center in India.

Materials and methods: Thirteen patients (≤17 years) attending CML outdoor from April 2008 to August 2012 were included in the analysis.

Statistical analysis used: The mean and median of various parameters were calculated using a Microsoft excel sheet. SPSS 16.0 version software was used to calculate OS and PFS.

Results: CML-CP was the most common phase at presentation. Maximum patients belonged to the 14 - 17 year old age group. Disease was common in the male sex. Splenic discomfort and asthenia were the most common symptoms and splenomegaly was the most common sign.

Conclusions: The treatment with Imatinib was effective and well-tolerated.

Keywords: Children and adolescents; chronic myeloid leukemia; imatinib.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Altman AJ. Chronic leukemias of childhood. Pediatr Clin North Am. 1988;35:765–87. - PubMed
    1. Dikshit RP, Nagrani R, Yeole B, Koyande S, Banawali S. Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years. Indian J Med Paediatr Oncology. 2011;32:96–100. - PMC - PubMed
    1. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. New Engl J Med. 2003;349:1451–64. - PubMed
    1. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel of behalf of the European Leukemia Net. Blood. 2006;108:1809–20. - PubMed
    1. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a children’s oncology group phase 1 study. Blood. 2004;104:2655–60. - PubMed